Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 12/20 | 0.46 |
| ▸ | TNF | P01375 | 8/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765068 | 0.82 | MMP13 (0.45) | MMP13 | |
| SCHEMBL8347364 | 0.82 | ADAM17 (0.48) | ADAM17DRD2DRD4 | |
| SCHEMBL6442206 | 0.81 | ADAM17 (0.56) | ADAM17TNFPARP1 | |
| SCHEMBL31039229 | 0.79 | ADAM17 (0.45) | ADAM17TNFPARP1 | |
| SCHEMBL14991264 | 0.77 | GAA (0.47) | ADAM17 | |
| SCHEMBL21768166 | 0.77 | ADAM17 (0.48) | ADAM17DRD2DRD4 | |
| SCHEMBL20773874 | 0.76 | PARK7 (0.50) | ADAM17TNF | |
| SCHEMBL31039203 | 0.76 | ADAM17 (0.46) | ADAM17TNF | |
| SCHEMBL31298892 | 0.76 | KDM4E (0.47) | ADAM17TNF | |
| SCHEMBL29507053 | 0.76 | PARK7 (0.50) | ADAM17TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | ADAM17 67/4885TNF 53/4885PARP1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.